← Oncology Approval Tracker

FDA DECISION ·

Padcev + Keytruda

enfortumab vedotin-ejfv + pembrolizumab · Astellas Pharma / Merck

Traditional approvalTraditional conversionBladder cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with locally advanced or metastatic urothelial cancer. This decision broadened the combination beyond the population previously eligible under accelerated approval.

LAMPGEN ANALYSIS

Why it matters

The combination moved into a wider first-line population, including patients who could receive cisplatin.

What research teams should watch

Use the applicable action date to distinguish the April cisplatin-ineligible cohort from this broader approval.

PRIMARY RECORDS

Sources